Albany, NY -- (SBWire) -- 04/03/2017 --Healthcare-associated infections (HAIs) are the ones that are contracted by patients while they are receiving treatment for another medical condition in a healthcare setting. Thus HAIs can be acquired at any place where healthcare is delivered. HAIs are generally caused by infectious agents, pathogens, fungi, bacteria, and viruses. The risk factors associated with these infections are use of indwelling medical devices, surgeries, injections, contaminated healthcare environment, communication of diseases between workers and patients, and improper use of antibiotics.

Browse Global Strategic Business Report:
http://www.transparencymarketresearch.com/healthcare-associated-infections-treatment.html

HAIs are a major cause of mortality and morbidity on a worldwide scale. Each year HAIs lead to thousands of deaths. A majority of HAIs include conditions such as urinary tract infections, surgical site infections, bloodstream infections, gastroenteritis, and pneumonia. The overall HAI treatment market can be classified on the basis of devices and pharmaceuticals used for HAI treatment. The major pharmaceuticals used in HAI treatment are viral pharmaceuticals, bacterial pharmaceuticals, and fungal pharmaceuticals. The major drug classes used in the pharmaceuticals segment are B-Lactam Antibiotics, cephalosporins, quinolones, glycopeptides, lincosamides, polypeptides, carbapenems, lipopeptides, penicillins, macrolides, tuberculosis, etracyclines, sulfonamides, and other such formulations. The medical devices segment can be further categorized into catheters and ventilation devices and in-line sterile IV filtration.

Download Exclusive Brochure of This Report :
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1223

The U.S. is the largest market for HAI treatment pharmaceuticals and devices. In the U.S., each year more than 1.5 million patients contract HAI. Recently Partners for Patients had introduced a USD 500 million grant to help hospitals and other healthcare providers to reduce HAIs in the U.S. it is expected that if successful, this program will save USD 50 billion of U.S. Medicare over the next ten years. The other markets for HAI treatment devices and pharmaceuticals are Asia-Pacific, Europe, and the Rest of the World. Some of the major players of this market include companies such as Merck, Johnson & Johnson, GlaxoSmithKline, Sharklet Technologies, Ondine Biomedical and some others.

This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include
North America
Asia Pacific
Europe
Rest of the World
This report provides comprehensive analysis of
Market growth drivers
Factors limiting market growth
Current market trends
Market structure
Market projections for upcoming years